AstraZeneca and Eli Lilly’s Alzheimer’s treatment to be fast tracked

AstraZeneca and Eli Lilly have received US Food and Drug Administration (FDA) fast track designation for the development of a treatment for Alzheimer’s.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

WATCH: Interview with Mythili Markowski, director at Regeneron

8 May 2026 LSIPR's senior reporter Marisa Woutersen speaks with Mythili Markowski of Regeneron on why new USPTO guidance is putting post-grant proceedings under the spotlight and how in-house teams are responding.

Americas

Teva can pursue monopoly claims over rival’s ‘exclusive pharmacy deal’

7 May 2026 A California judge has denied Corcept’s bid to dismiss the lawsuit over its drug for a rare hormonal disorder, allowing the litigation to proceed on all core counts.

Americas

US judge allows rare patent defence in ‘world’s smallest heart pump’ suit

5 May 2026 J&J’s Abiomed can proceed with its non-infringement defence despite potential future appellate reversal, in a week when both parties in the case were dealt wins and losses in their clash over Impella devices.

More features

WATCH: Interview with Mythili Markowski, director at Regeneron

IP in the deal room: The risks that bite before, during and after closing

Teva can pursue monopoly claims over rival’s ‘exclusive pharmacy deal’

Five generations at work: How teams are bridging the gap

Kilpatrick adds tech patent litigator and China expert to Chicago office

US judge allows rare patent defence in ‘world’s smallest heart pump’ suit

WATCH: John Ward, trademarks VP and associate GC of Moderna, at INTA

WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular

AstraZeneca and Eli Lilly’s Alzheimer’s treatment to be fast tracked

More on this story

Editor's picks

Editor's picks

More features